Clinical Trial Update: Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation [Phase 2]

View source ↗

Summary

Phase 2 study evaluating ALXN2030 for antibody-mediated rejection in kidney transplant patients is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antibody-mediated Rejection

Drugs mentioned

• ALXN2030

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Antibody-Mediated Rejection, Kidney Transplantation | Phase 2 | Status: RECRUITING